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Sir,
A large number of studies have been published investigating the
occurrence of second primary cancers following the diagnosis of
an ‘index’ cancer. The standard method of analysis is to compare
the observed numbers of subsequent cancers with the numbers
expected on the basis of cancer incidence rates in the general
population (accounting for age, sex and time period). To do this,
the number of ‘person-years at risk’ is calculated, with the ‘at risk’
period for each individual starting at the date of diagnosis of the
index cancer and terminating at the study cutoff date, the date of
death or loss to follow-up, or the date of diagnosis of the
subsequent cancer of interest. If the treatment for the index cancer
entails removal of the organ in which this occurred, then it seems
sensible when investigating the occurrence of second cancers at the
same anatomical site to terminate the ‘at-risk’ period at the point
when the removal occurred, as a subsequent primary cancer
cannot arise in an organ that no longer exists.
For example, a woman with breast cancer who undergoes a total
mastectomy is no longer at risk for subsequent ipsilateral breast
cancer, but she does remain at risk for subsequent contralateral
breast cancer. Consequently, ipsilateral and contralateral cancers
should be treated differently in the calculation of time at risk. For
contralateral breast cancer, the standard method of calculating
time at risk applies. However, for ipsilateral breast cancer the ‘at-
risk’ period should be truncated at the date of mastectomy if this
has been performed. Expected numbers of subsequent ipsilateral
and contralateral breast cancers are then calculated by multiplying
the ‘at-risk’ period by half the standard breast cancer incidence
rate, and the two added together to give the total expected number
of subsequent breast cancers.
Failure to correct for mastectomies leads to underestimation of
the standardised incidence ratios (SIRs) for ipsilateral tumours.
This is because, without the correction, mastectomy cases are
considered to be at risk until the cutoff date at the end of the study.
As a result, person-years at risk (and hence estimated expected
numbers) are inflated. An example of this effect is given in Table 1,
which shows the observed numbers of subsequent invasive breast
cancers in a series of 13269 women diagnosed with breast
carcinoma in situ (Robinson et al, 2008), together with the
expected numbers calculated using the standard methodology (‘no
correction’) and after applying the correction for mastectomies as
described above (‘correction’). Without the correction, the SIR for
ipsilateral breast cancer is lower than for contralateral tumours.
After applying the correction, this is reversed. It seems intuitively
more likely that a second breast cancer would develop in the breast
where in situ disease had been detected.
This problem has been recognised for some time. Franceschi
(1997) pointed out in an editorial that it is ‘worth bearing in mind
that the computation of the expected number of breast cancers in
prospective studies of women whose breasts have been partly
removed is open to discussion’. Levi et al (1998) concurred, adding
that expected values are ‘likely to be overestimated’. However, this
effect is rarely taken into account. Rawal et al (2005) analysed
ipsilateral and contralateral breast cancers separately, but it
appears that mastectomies were not accounted for. Similarly,
Soerjomataram et al (2006) calculated expected numbers and
SIRs for breast cancer following breast carcinoma in situ separately
for ipsilateral and contralateral tumours, but it is not clear
whether they allowed for mastectomies. Moreover, they applied
the overall incidence rates from the general population to each
group (rather than half-rates), thus leading to expected numbers
which were twice, and SIRs which were half, the true values.
This issue of applying half-rates was addressed by Peto (1987)
in the context of calculating expected numbers of contralateral
breast cancers.
Similar arguments would apply in other situations involving
organ removal – for example, hysterectomies should be taken into
account when looking at subsequent occurrences of cervical or
uterine cancers. These issues should be borne in mind when
investigating the occurrence of second cancers.
Table 1 Effect of mastectomy ‘correction’ on estimated standardised
incidence ratios (SIRs)
Side Observed Expected SIR
Contralateral 286 165.99 1.72
Ipsilateral
No correction 226 167.08 1.35
Correction 226 95.45 2.37
Total
No correction 512 333.07 1.54
Correction 512 261.44 1.96
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